Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions

Advanced Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

CKD-512

Orally administered BID

COMBINATION_PRODUCT

Pembrolizumab

Intravenous (IV) Infusion

Trial Locations (1)

Severance Hospital, Yonsei University Health System, Seoul